"I would accept that, the problem is, that all you have ever done is down play results, announcements etc..."
Predominantly, I have expressed the view that the company is under-funded to self-sustaining commercialisation. A view, a the risk of being brazen, has proven to be appropriate.
You have always been free to refute or disprove that sentiment, to the extent that you disagreed with it. Along with any other things I have said.
That's the nature of a stock discussion forum.
Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-85
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |